1. Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial. Issue 6 (30th November 2022) Authors: Mo, Zhao-Jun; Bi, Zhao-Feng; Sheng, Wei; Chen, Qi; Huang, Teng; Li, Ming-Qiang; Cui, Xue-Lian; Wangjiang, Ya-Hui; Lin, Bi-Zhen; Zheng, Feng-Zhu; Sun, Guang; Li, Ya-Fei; Zheng, Ya; Zhuang, Si-Jie; Su, Ying-Ying; Pan, Hui-Rong; Huang, Shou-Jie; Wu, Ting; Zhang, Jun; Xia, Ning-Shao Journal: Human vaccines & immunotherapeutics Issue: Volume 18:Issue 6(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗